Skip to main content

Table 2 Risk of SPC a by gender and first cancer site, France 1989–2004 (N = 289,967)

From: The effect of patient characteristics on second primary cancer risk in France

 

Males

Females

(N = 160, 807)

(N = 129,160)

First cancer site

O

E

PYR

SIR

EARb

(95% CI)

O

E

PYR

SIR

EARb

(95% CI)

Lip

111

80.66

4,081

1.38*

74.3*

(26.1-129.9)

13

8.44

806

1.54

56.6

(-18.9-171.2)

Tongue and lingual tonsil

329

90.84

6,794

3.62*

350.5*

(299.6-405.8)

41

15.99

1,886

2.56*

132.6*

(71.2-210.2)

Oral cavity

536

129.77

10,034

4.13*

404.9*

(360.6-452.0)

83

23.36

2,863

3.55*

208.3*

(149.3-277.8)

Salivary glands

29

20.45

1,480

1.42

57.8

(-7.0-143.3)

14

12.38

1,569

1.13

10.3

(-30.1-70.8)

Oropharynx

550

129.86

10,157

4.24*

413.7*

(369.3-460.9)

52

14.54

1,813

3.58*

206.6*

(134.0-295.9)

Nasopharynx

13

12.90

1,223

1.01

0.8

(-49.0-76.2)

8

3.33

535

2.41*

87.4*

(2.2-232.6)

Hypopharynx

496

129.23

9,334

3.84*

392.9*

(347.2-441.8)

27

4.40

577

6.13*

391.8*

(232.1-604.9)

Head and neckc

1,981

509.07

38,731

3.89*

380.0*

(357.8-403.1)

214

62.40

7,781

3.43*

194.8*

(159.2-234.3)

Oesophagus

290

119.03

7,367

2.44*

232.1*

(188.1-280.1)

27

11.27

1,244

2.40*

126.5*

(52.4-225.2)

Stomach

240

233.16

12,773

1.03

5.4

(-17.7-30.7)

87

83.55

8,739

1.04

3.9

(-15.9-27.2)

Small intestine

32

31.37

1,848

1.02

3.4

(-51.4-74.7)

15

15.39

1,716

0.97

-2.3

(-40.8-54.5)

Colorectum

1,996

1,843.60

97,268

1.08*

15.7*

(6.8-24.9)

935

792.53

87,123

1.18*

16.4*

(9.6-23.5)

Colon

1,185

1,060.19

55,504

1.12*

22.5*

(10.5-35.0)

590

491.42

54,649

1.20*

18.0*

(9.5-27.1)

Rectum

810

783.28

41,747

1.03

6.4

(-6.7-20.2)

344

300.88

32,443

1.14*

13.3*

(2.4-25.1)

Liver, primary

135

120.50

6,749

1.12

21.5

(-10.8-58.2)

23

13.82

1,709

1.66*

53.7*

(4.4-121.1)

Gallbladder and biliary tract

30

38.16

1,950

0.79

-41.9

(-91.9-23.9)

31

24.89

2,463

1.25

24.8

(-15.5-77.6)

Pancreas

33

49.39

2,948

0.67*

-55.6*

(-90.5--10.3)

25

23.53

2,730

1.06

5.4

(-27.0-49.0)

Nasal cavities and sinuses

50

42.29

2,430

1.18

31.7

(-21.3-97.2)

3

5.90

650

0.51

-44.5

(-81.4-44.1)

Larynx

853

323.02

19,900

2.64*

266.3*

(238.0-296.1)

58

16.93

1,995

3.43*

205.9*

(135.9-291.0)

Lung, bronchus and trachea

855

599.96

41,161

1.43*

62.0*

(48.3-76.4)

96

72.95

9,446

1.32*

24.4*

(5.1-46.9)

Pleura

8

13.92

776

0.57

-76.2

(-134.9-23.8)

3

2.45

284

1.22

19.3

(-65.1-222.3)

Bone and cartilages

16

11.53

2,306

1.39

19.4

(-10.4-62.7)

11

8.25

2,087

1.33

13.2

(-13.2-54.8)

Soft tissue

67

55.74

4,965

1.20

22.7

(-7.7-59.1)

39

24.00

3,951

1.62*

38.0*

(9.4-74.2)

Melanoma of skin

303

258.43

20,881

1.17*

21.3*

(5.5-38.6)

288

208.83

32,126

1.38*

24.6*

(14.6-35.6)

Breast

52

45.45

2,282

1.14

28.7

(-29.0-99.6)

2,476

1,885.48

351,434

1.31*

16.8*

(14.1-19.6)

Cervix uteri

-

-

-

-

-

-

265

173.92

28,122

1.52*

32.4*

(21.4-44.4)

Corpus uteri

-

-

-

-

-

-

511

370.65

41,147

1.38*

34.1*

(23.6-45.4)

Ovary and uterine adnexa

-

-

-

-

-

-

189

168.03

22,829

1.12

9.2

(-2.2-21.9)

Vagina and vulva

-

-

-

-

-

-

59

39.51

4,219

1.49*

46.2*

(12.8-86.7)

Prostate

3,880

3,500.52

230,582

1.11*

16.5*

(11.2-21.8)

-

-

-

-

-

-

Testis

86

59.42

19,448

1.45*

13.7*

(4.8-24.1)

-

-

-

-

-

-

Penis

43

42.20

2,303

1.02

3.5

(-48.1-68.3)

-

-

-

-

-

-

Bladder

1,192

729.56

38,002

1.63*

121.7*

(104.1-140.0)

99

79.73

7,772

1.24*

24.8*

(0.9-52.5)

Kidney

660

471.41

28,385

1.40*

66.4*

(49.0-84.9)

198

149.07

17,327

1.33*

28.2*

(12.9-45.3)

Melanoma of choroid

23

19.49

1,361

1.18

25.8

(-36.1-110.4)

14

12.84

1,465

1.09

7.9

(-35.4-72.7)

Brain

24

30.03

5,546

0.80

-10.9

(-26.4-10.2)

20

16.84

4,506

1.19

7.0

(-10.3-31.2)

Thyroid gland

88

62.22

7,369

1.41*

35.0*

(11.3-62.7)

244

174.12

31,397

1.40*

22.3*

(12.8-32.6)

Hodgkin’s disease

69

40.59

8,338

1.70*

34.1*

(15.7-56.0)

38

22.16

6,930

1.72*

22.9*

(6.8-43.3)

Non-Hodgkin’s lymphoma

448

348.23

26,008

1.29*

38.4*

(22.8-55.1)

229

185.26

22,997

1.24*

19.0*

(6.5-32.8)

Multiple myeloma

133

125.42

6,934

1.06

10.9

(-20.3-46.4)

73

66.51

6,946

1.10

9.3

(-13.4-36.4)

Leukaemia

377

323.41

22,217

1.17*

24.1*

(7.4-42.1)

173

130.86

17,269

1.32*

24.4*

(10.0-40.5)

Acute lymphatic leukaemia

4

3.21

3,064

1.25

2.6

(-7.0-23.0)

7

2.91

2,571

2.41

15.9

(-0.4-44.8)

Chronic lymphatic leukaemia

276

219.48

11,261

1.26*

50.2*

(22.1-80.9)

123

91.97

9,091

1.34*

34.1*

(11.3-60.3)

Acute myeloid leukaemia

21

23.63

2,585

0.89

-10.2

(-41.2-32.8)

23

12.37

2,491

1.86*

42.7*

(8.8-88.9)

Chronic myeloid leukaemia

43

47.36

3,291

0.91

-13.3

(-49.4-32.1)

14

16.78

2,234

0.83

-12.4

(-40.9-30.0)

Other sitesd

542

412.95

25,949

1.31*

49.7*

(32.5-68.1)

211

186.09

22,084

1.13

11.3

(-1.2-25.1)

All sites d

14,555

10,514.87

689,115

1.38*

58.6*

(55.2-62.1)

6,671

5,040.73

751,845

1.32*

21.7*

(19.6-23.8)

  1. SPC, second primary cancer; O, Observed; E, Expected; PYR, person-years at risk; SIR, standardized incidence ratio; EAR, excess absolute risk; CI, confidence interval.
  2. aExcluding SPC occurring in the same subsite as the first primary cancer.
  3. bNumber of excess cancers per 10,000 person-years at risk.
  4. cHead and neck site includes tongue and lingual tonsil, oral cavity, oropharynx, nasopharynx, hypopharynx and other oral cavity and pharynx.
  5. dExcluding non-melanoma skin cancer.
  6. *P < .05.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us